IBDEI1HW ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23917,0)
 ;;=I13.0^^107^1196^30
 ;;^UTILITY(U,$J,358.3,23917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23917,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,23917,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,23917,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,23918,0)
 ;;=I13.2^^107^1196^31
 ;;^UTILITY(U,$J,358.3,23918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23918,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 5 Chr Kdny
 ;;^UTILITY(U,$J,358.3,23918,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,23918,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,23919,0)
 ;;=I13.10^^107^1196^32
 ;;^UTILITY(U,$J,358.3,23919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23919,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,23919,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,23919,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,23920,0)
 ;;=I13.11^^107^1196^33
 ;;^UTILITY(U,$J,358.3,23920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23920,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 5 Chr Kdny
 ;;^UTILITY(U,$J,358.3,23920,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,23920,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,23921,0)
 ;;=E03.9^^107^1196^43
 ;;^UTILITY(U,$J,358.3,23921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23921,1,3,0)
 ;;=3^Hypothyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,23921,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,23921,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,23922,0)
 ;;=M54.5^^107^1196^46
 ;;^UTILITY(U,$J,358.3,23922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23922,1,3,0)
 ;;=3^Low Back Pain
 ;;^UTILITY(U,$J,358.3,23922,1,4,0)
 ;;=4^M54.5
 ;;^UTILITY(U,$J,358.3,23922,2)
 ;;=^5012311
 ;;^UTILITY(U,$J,358.3,23923,0)
 ;;=C61.^^107^1196^47
 ;;^UTILITY(U,$J,358.3,23923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23923,1,3,0)
 ;;=3^Malig Neopl Prostate
 ;;^UTILITY(U,$J,358.3,23923,1,4,0)
 ;;=4^C61.
 ;;^UTILITY(U,$J,358.3,23923,2)
 ;;=^267239
 ;;^UTILITY(U,$J,358.3,23924,0)
 ;;=F11.20^^107^1196^53
 ;;^UTILITY(U,$J,358.3,23924,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23924,1,3,0)
 ;;=3^Opioid Dependence,Uncomplicated
 ;;^UTILITY(U,$J,358.3,23924,1,4,0)
 ;;=4^F11.20
 ;;^UTILITY(U,$J,358.3,23924,2)
 ;;=^5003127
 ;;^UTILITY(U,$J,358.3,23925,0)
 ;;=M19.90^^107^1196^54
 ;;^UTILITY(U,$J,358.3,23925,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23925,1,3,0)
 ;;=3^Osteoarthritis,Unspec
 ;;^UTILITY(U,$J,358.3,23925,1,4,0)
 ;;=4^M19.90
 ;;^UTILITY(U,$J,358.3,23925,2)
 ;;=^5010853
 ;;^UTILITY(U,$J,358.3,23926,0)
 ;;=M85.80^^107^1196^55
 ;;^UTILITY(U,$J,358.3,23926,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23926,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,23926,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,23926,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,23927,0)
 ;;=M81.0^^107^1196^56
 ;;^UTILITY(U,$J,358.3,23927,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23927,1,3,0)
 ;;=3^Osteoporosis,Age-Related w/o Fx
 ;;^UTILITY(U,$J,358.3,23927,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,23927,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,23928,0)
 ;;=I73.9^^107^1196^63
 ;;^UTILITY(U,$J,358.3,23928,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23928,1,3,0)
 ;;=3^Peripheral Vascular Disease,Unspec
 ;;^UTILITY(U,$J,358.3,23928,1,4,0)
 ;;=4^I73.9
 ;;^UTILITY(U,$J,358.3,23928,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,23929,0)
 ;;=R21.^^107^1196^66
 ;;^UTILITY(U,$J,358.3,23929,1,0)
 ;;=^358.31IA^4^2
